Compare Emerson Electric Co. (EMR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Emerson Electric Co. trades at $160.99 (market cap $89.85B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Emerson Electric Co. is far larger — about 91.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Emerson Electric Co. pays a 1.38% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EMR | MRVI | |
|---|---|---|
Market Cap | $89.85B | $977.37M |
Volume | 2,769,354 | 2,742,564 |
Sector | Industrials | Health |
52-Week High | $164.38 | $9.00 |
52-Week Low | $123.30 | $2.83 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $100.93B | $1.08B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $163.50, up 0.64% today, with a bullish technical outlook and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust profitability with a 13.83% net income margin and trades near the consensus price target of $165.90. Recent cash flow trends indicate improving operational performance, while analyst sentiment remains positive with 53% buy ratings.
EMR offers steady growth potential driven by earnings consistency and favorable analyst targets, but risks include elevated valuation multiples and debt level fluctuations. The stock's proximity to resistance at $164 suggests near-term consolidation may occur, yet fundamental strength supports a constructive long-term outlook for investors seeking industrial sector exposure.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
